Rate My Professor Paul Chin

Paul Chin has authored or co-authored over 59 publications, accumulating approximately 787 citations. Notable works include 'Pharmacogenetics of statin-induced myotoxicity' (Frontiers in Genetics, 2020), 'High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment' (Alimentary Pharmacology & Therapeutics, 2012), 'Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C' (Drugs in R&D, 2014), 'Anticoagulation use and clinical outcomes after major bleeding on dabigatran or warfarin in atrial fibrillation' (Stroke, 2017), and 'A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time' (British Journal of Clinical Pharmacology, 2014). Recent publications encompass 'Indication-based prescribing and prescribing with indications, effects on documentation, medicines use, and clinical outcomes: A systematic review' (International Journal of Medical Informatics, 2026), 'Oral anticoagulation for adults with atrial fibrillation or venous thromboembolism' (Australian Prescriber, 2025), and 'Rivaroxaban plasma concentrations cannot be predicted from coagulation assays: Real-life experience from a tertiary hospital in New Zealand' (Therapeutic Drug Monitoring, 2025). His contributions advance pharmacokinetic monitoring, dosing optimization, pharmacogenetics, and prescribing safety, impacting clinical practice in hospital settings. Presentations include educational and clinical utility of electronic pre-prescribing at the AMEE Annual Conference (2025).